Share this article
Share this article
ResearchAndMarkets.com s offering.
Facial Tissues Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global facial tissues market as it emerges from the COVID-19 shut down.
Major players in the facial tissues market are Kimberly-Clark, Procter and Gamble, APP, Hengan, Vinda, C&S PAPER, Metsa Tissue, WEPA, Cascades and KP Tissue.
The global facial tissues market is expected to grow from $11.98 billion in 2020 to $12.68 billion in 2021 at a compound annual growth rate (CAGR) of 5.8%.
The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $15.92 billion i
/PRNewswire/ Family planning and fertility benefits are becoming more mainstream with employers seeking to demonstrate inclusivity and attract or retain.
Cape Cod s Code1Supply Enables Businesses to Keep Safety at Forefront
Company Offers MA Businesses Easy Access to Life-Saving Medical Supplies
News provided by
Share this article
Share this article
SOUTH YARMOUTH, Mass., May 19, 2021 /PRNewswire/ Cape Cod-based Code1Supply, a leading distributor of best-in-class medical diagnostics, brand-name supplies and equipment and provider of CPR training equipment and student materials, provides the tools Massachusetts businesses need to prepare for large summer crowds as COVID-19 restrictions are lifted throughout the Commonwealth.
Code1Supply offers medical supplies and equipment for businesses and communities, including life-saving AED kits such as the Phillips HeartStart OnSite AED for use in businesses, restaurants and summer camps. It is the only defibrillator in the market that is available without a prescription that can be used by people with no medical training. Features include:
Oncopeptides Partners with Veeva to Drive More Effective Engagement Ahead of First Commercial Launch
Veeva Link provides biotech with valuable market insights about top scientific and clinical leaders
News provided by
Share this article
PLEASANTON, Calif., May 17, 2021 /PRNewswire/
Veeva Systems (NYSE: VEEV) today announced a strategic partnership with Oncopeptides to support the launch of the global biotech s first commercial product. Using Veeva Link for real-time customer intelligence, Oncopeptides recently launched PEPAXTO® (melphalan flufenamide), the first anticancer peptide-drug conjugate approved by the U.S. Food and Drug Administration (FDA) for multiple myeloma. Engaging the right healthcare providers (HCPs) is key in determining how fast we can reach patients battling difficult-to-treat hematological diseases, said Mohamed H. Ladha, general manager of the U.S. business unit at Oncopeptides. Veeva Link has given our medical and commercial teams the strateg